A drug testing industry association and a pharmaceutical company are asking a federal court to stop the Trump administration from moving ahead with federal cannabis rescheduling, at least for now. The request is tied to ongoing litigation that challenges the proposed policy change.
According to the filing described in the report, the groups argue that reclassifying marijuana under federal law could lead to greater misuse. Their position adds a new legal and political obstacle to a long-running national debate over how cannabis should be treated by regulators.
The case also underscores the competing interests surrounding marijuana policy. Supporters of rescheduling have argued that federal rules should better reflect current medical and state-level cannabis laws, while opponents say loosening restrictions could create new public health, workplace and enforcement concerns.
If the court agrees to pause the process, it could delay a major federal shift on cannabis while the broader challenge plays out. That would keep the spotlight on how marijuana reform affects industries such as drug testing, pharmaceuticals and other sectors closely tied to federal policy.
